Valdecoxib

MUSCULO-SKELETAL SYSTEM

Key facts

Valdecoxib is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 2001. DrugCentral lists 37 molecular targets, including PTGS2, Carbonate dehydratase and CA12. Recorded indications include Acute postoperative pain.

• Approval status: ofm (first approved 2001 by the FDA).
• Molecular targets: PTGS2, Carbonate dehydratase, CA12 and CA9 (37 listed in DrugCentral).
• Indications: Acute postoperative pain.
• ATC code: M01AH03 (Coxibs).
• Molecular formula: C16H14N2O3S; molecular weight 314.36 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Acute postoperative pain

Off-label uses (3)

• Dysmenorrhea
• Osteoarthritis
• Rheumatoid arthritis

Mechanism & targets

Molecular targets (37)

Target	Gene	Action	Activity
Prostaglandin G/H synthase 2	PTGS2	inhibitor	IC50 8.30
Carbonate dehydratase	—	unknown	Ki 8.28
Carbonic anhydrase 12	CA12	unknown	Ki 7.89
Carbonic anhydrase 9	CA9	unknown	IC50 7.57
Alpha carbonic anhydrase	CA	unknown	Ki 7.54
Carbonic anhydrase	NCE103	unknown	Ki 7.37
Carbonic anhydrase 2	CA2	unknown	IC50 7.37
Carbonic anhydrase 15	Ca15	unknown	Ki 7.18
Carbonic anhydrase 5B, mitochondrial	CA5B	unknown	Ki 7.06
Carbonic anhydrase	—	unknown	Ki 7.01
Carbonic anhydrase 14	CA14	unknown	Ki 6.97
Carbonic anhydrase	—	unknown	Ki 6.89
Carbonic anhydrase	—	unknown	Ki 6.79
Carbonic anhydrase 4	CA4	unknown	Ki 6.47
Delta carbonic anhydrase	ca1	unknown	Ki 6.42
Carbonic anhydrase 13	Ca13	unknown	Ki 6.37
Carbonic anhydrase 13	CA13	unknown	Ki 6.37
Astrosclerin-3	—	unknown	Ki 6.29
Carbonic anhydrase, alpha family	—	unknown	Ki 6.28
Carbonic anhydrase 6	CA6	unknown	Ki 6.24

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2001-11-16	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
M01AH03	MUSCULO-SKELETAL SYSTEM › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS › Coxibs

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Drug hypersensitivity	226.0
Sacroiliitis	59.2

Chemical structure

• Molecular formula: C₁₆H₁₄N₂O₃S
• Molecular weight: 314.36 g/mol
• CAS number: 181695-72-7
• InChIKey: LNPDTQAFDNKSHK-UHFFFAOYSA-N
• PubChem CID: 119607

CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Valdecoxib used for?

DrugCentral lists the following indications for Valdecoxib: Acute postoperative pain.

How does Valdecoxib work?

Its molecular targets in DrugCentral include PTGS2 (inhibitor), Carbonate dehydratase, CA12 and CA9.

When was Valdecoxib first approved?

Valdecoxib was first approved by the FDA in 2001.

What is the chemical formula of Valdecoxib?

Valdecoxib has the molecular formula C16H14N2O3S and a molecular weight of 314.36 g/mol.

Sources

• DrugCentral drug card 2799 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL865 — compound record and bioactivity
• PubChem CID 119607 — chemical identifiers
• DrugBank DB00580 — drug record
• FDA UNII 2919279Q3W — substance identity
• DailyMed: FDA labels for Valdecoxib — current prescribing information (label search)
• UniProt P35354 (PTGS2) — target protein
• UniProt O43570 (CA12) — target protein
• UniProt Q16790 (CA9) — target protein
• UniProt P00918 (CA2) — target protein
• UniProt Q9Y2D0 (CA5B) — target protein
• UniProt Q9ULX7 (CA14) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.